Ras as a target in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ras proteins are key regulators of cell growth and are frequently mutated in human cancers.
• Ras activation initiates downstream signaling pathways, including the Raf-1/mitogen-activated protein kinase pathway.
• Post-translational modifications, such as farnesylation, are essential for Ras protein function and membrane localization.

Purpose of the Study:

• To explore therapeutic strategies targeting Ras proteins in cancer.
• To evaluate the efficacy of farnesyl protein transferase (FPT) inhibitors.
• To investigate the potential of immunotherapy for Ras-mutated tumors.

Main Methods:

• Inhibition of farnesyl protein transferase (FPT) to block Ras post-translational modification.
• Assessment of anti-proliferative effects in vitro and in human cancer xenograft models.
• Evaluation of Ras mutations as neo-epitopes for T-cell recognition in immunotherapy.

Main Results:

• Farnesylation inhibition effectively ablates Ras activity, leading to significant anti-proliferative effects.
• FPT inhibitors are undergoing clinical trials (Phase I and II) with pharmacokinetic and dynamic assessments.
• Ras mutations can create neo-epitopes, making Ras-mutated tumors potential targets for immunotherapy.

Conclusions:

• Targeting Ras post-translational modification via FPT inhibitors is a rational therapeutic strategy.
• Immunotherapy targeting Ras mutations presents a novel approach for cancer treatment.
• Both FPT inhibition and immunotherapy warrant further clinical evaluation for Ras-driven cancers.